ZCZeshan Chen

Zeshan Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zeshan Chen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Guanzhu Wu

    Second Ward, Department of Respiratory and Critical Care Medicine, Liuzhou Hospital of Traditional Chinese Medicine, Liuzhou, Guangxi 545000, P.R. China

    1 shared publication
  • Hualing Zhang

    Second Ward, Department of Respiratory and Critical Care Medicine, Liuzhou Hospital of Traditional Chinese Medicine, Liuzhou, Guangxi 545000, P.R. China

    1 shared publication
  • Miaodong Wang

    Department of Traditional Chinese Medicine, Jinhua Central Hospital, Jinhua, People’s Republic of China

    1 shared publication
  • Qin He

    Department of Traditional Chinese Medicine, Jinhua Central Hospital, Jinhua, People’s Republic of China

    1 shared publication
  • Weixing Guo

    Second Ward, Department of Respiratory and Critical Care Medicine, Liuzhou Hospital of Traditional Chinese Medicine, Liuzhou, Guangxi 545000, P.R. China

    1 shared publication
  • Yijue Qin

    Department of Traditional Chinese Medicine, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning City, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    MicroRNA‑21: A potential therapeutic target in lung cancer (Review)

    by Zhouqiang Li, Hualing Zhang, Zeshan Chen, Guanzhu Wu, Weixing Guo, Yun Li

    In this review, the role of microRNA‑21 (miRNA‑21) as an oncogene in lung cancer was investigated. Studies have shown that miRNA‑21 can promote the progression of lung cancer by targeting downstream target genes, and its expression can be modulated by transcription factors, DNA methylation or competitive endogenous RNA as an upstream regulator. This review highlights that miRNA‑21 can promote the progression of lung cancer through multiple signaling pathways, with a focus on the PI3K/AKT, MEK/ERK, TGF‑β/SMAD, Hippo, NF‑κB and STAT3 signaling pathways. Mechanistically, miRNA‑21 plays an important role in the progression of lung cancer by regulating multiple biological processes, such as proliferation, invasion, metastasis, apoptosis and angiogenesis in lung cancer cells. Higher expression of miRNA‑21 is associated with chemotherapy, radiotherapy and immune resistance in lung cancer. Targeting these molecular pathways may be a novel therapeutic strategy for treating lung cancer. Additionally, miRNA‑21 can serve as a biomarker for lung cancer diagnosis, prognosis and treatment response. This review also summarized the following: i) Current methods employed to inhibit the expression of miRNA‑21 in lung cancer, including CRISPR/Cas9 technology; ii) the application of natural anticancer agents, oligonucleotides, small molecules and miRNA sponges; and iii) the nano‑delivery systems developed for miRNA‑21 inhibitors. Finally, the advancements in research on miRNA mimics and inhibitors in clinical trials, which may promote the application of miRNA‑21 in clinical trials in lung cancer, were discussed. Given that lung cancer is a considerable public health challenge, these studies provide new ways of treating patients with lung cancer.


  • Open Access

    Integrating multiomics analysis and machine learning to refine the molecular subtyping and prognostic analysis of stomach adenocarcinoma

    by Miaodong Wang, Qin He, Zeshan Chen, Yijue Qin

    Stomach adenocarcinoma (STAD) is a common malignancy with high heterogeneity and a lack of highly precise treatment options. We downloaded the multiomics data of STAD patients in The Cancer Genome Atlas (TCGA)-STAD cohort, which included mRNA, microRNA, long non-coding RNA, somatic mutation, and DNA methylation data, from the sxdyc website. We synthesized the multiomics data of patients with STAD using 10 clustering methods, construct a consensus machine learning-driven signature (CMLS)-related prognostic models by combining 10 machine learning methods, and evaluated the prognosis models using the C-index. The prognostic relationship between CMLS and STAD was assessed using Kaplan-Meier curves, and the independent prognostic value of CMLS was determined by univariate and multivariate regression analyses. we also evaluated the immune characteristics, immunotherapy response, and drug sensitivity of different CMLS groups. The results of the multiomics analysis classified STAD into three subtypes, with CS1 resulting in the best survival outcome. In total, 10 hub genes (CES3, AHCYL2, APOD, EFEMP1, CYP1B1, ASPN, CPE, CLIP3, MAP1B, and DKK1) were screened and constructed the CMLS was significantly correlated with prognosis in patients with STAD and was an independent prognostic factor for patients with STAD. Using the CMLS risk score, all patients were divided into a high CMLS group and a low CMLS group. Patients in the low-CMLS group had better survival, more enriched immune cells, and higher tumor mutation load scores, suggesting better immunotherapy responsiveness and a possible “hot tumor” phenotype. Patients in the high-CMLS group had a significantly poorer prognosis and were less sensitive to immunotherapy but were likely to benefit more from chemotherapy and targeted therapy. In this study, 10 clustering methods and 10 machine learning methods were combined to analyze the multiomics of STAD, classify STAD into three subtypes, and constructed CMLS-related prognostic model features, which are important for accurate management and effective treatment of STAD.